[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100364916":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":35,"centralContacts":36,"locations":44,"responsibleParty":64,"collaborators":66,"id":69,"slug":35,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":27,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":35,"studyType":82,"phases":83,"briefSummary":86,"conditions":87,"keywords":35,"overallStatus":47,"whyStopped":35,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Genesis Athens Clinic","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants receiving PRP treatment","EXPERIMENTAL","Women presenting with POI, 25-39 years of age, treated with autologous PRP intra ovarian infusion",[13],"Biological: Autologous Platelet Rich Plasma",{"label":15,"type":16,"description":17,"interventionNames":18},"Participants receiving Platelet Free Plasma (PFP) treatment","PLACEBO_COMPARATOR","Women presenting with POI, 25-39 years of age, treated with autologous PFP intra ovarian infusion",[19],"Biological: Placebo-Platelet Free Plasma",[21,29],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BIOLOGICAL","Autologous Platelet Rich Plasma","Autologous PRP intra ovarian infusion",[9],[27,28],"PRP","Platelet Rich Plasma",{"type":22,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Placebo-Platelet Free Plasma","Autologous PFP intra ovarian infusion",[15],[34],"PFP",null,[37,42],{"name":38,"role":39,"phone":40,"phoneExt":35,"email":41},"Mara Simopoulou, PhD","CONTACT","+306979234100","marasimopoulou@hotmail.com",{"name":43,"role":39,"phone":35,"phoneExt":35,"email":35},"Agni Pantou, MD, PhD Candidate",[45],{"facility":46,"status":47,"city":48,"state":35,"zip":49,"country":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Genesis AC","RECRUITING","Athens","15232","Greece",{"type":52,"coordinates":53},"Point",[54,55],23.72784,37.98376,{"lat":55,"lon":54},[58,59,62],{"name":38,"role":39,"phone":35,"phoneExt":35,"email":35},{"name":60,"role":61,"phone":35,"phoneExt":35,"email":35},"Agni Pantou, MD","PRINCIPAL_INVESTIGATOR",{"name":63,"role":61,"phone":35,"phoneExt":35,"email":35},"Konstantinos Pantos, MD, PhD",{"type":65,"investigatorFullName":35,"investigatorTitle":35,"investigatorAffiliation":35,"oldNameTitle":35,"oldOrganization":35},"SPONSOR",[67],{"name":68,"class":6},"National and Kapodistrian University of Athens","100364916",false,"NCT04031456","Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients","Investigating Reactivation of Ovarian Function Following Autologous PRP Intra-ovarian Infusion in POI Patients","Inclusion Criteria:\n\n* Age \\\u003C 40 years, presenting with amenorrhea or menstrual cycle irregularities for at least four months, and elevated FSH levels \\>25 IU\u002FL recorded on two occasions \\>4 weeks apart\n* Normal Karyotype: 46, XX\n* Discontinuation of any complementary\u002Fadjuvant treatment including hormone replacement, acupuncture, and botanotherapy, for at least three months prior to recruitment.\n* Willing to comply with study requirements\n\nExclusion Criteria:\n\n* Any pathological disorder related to reproductive system anatomy\n* AMH \\> 8 pmol\u002FL\n* Endometriosis\n* Adenomyosis\n* Fibroids and adhesions\n* Infections in reproductive system\n* Current or previous diagnosis of cancer in reproductive system\n* History of familiar cancer in reproductive system\n* Severe male factor infertility\n* Prior referral for PGT\n* Ovarian inaccessibility\n* Endocrinological disorders (Hypothalamus-Pituitary disorders, thyroid dysfunction, diabetes mellitus, metabolic syndrome)\n* BMI\\>30 kg\u002Fm2 or BMI\\\u003C18.5 kg\u002Fm2\n* Systematic autoimmune disorders",true,"FEMALE","25 Years","39 Years",{"count":80,"type":81},100,"ESTIMATED","INTERVENTIONAL",[84,85],"PHASE2","PHASE3","Autologous PRP intra ovarian infusion may restore ovarian function, may promote folliculogenesis and may improve patients' hormonal profile in patients presenting with POI.",[88,89,90,91,92],"Menopause, Premature","Menopause Related Conditions","Menopausal Syndrome","Premature Ovarian Failure","Ovarian Failure, Premature","2024-12-20",{"date":95,"type":96},"2024-12-24","ACTUAL",{"date":98,"type":96},"2019-07-30",{"date":100,"type":81},"2026-07-30",{"name":5,"class":6},1]